Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Evaluation of the Impact of Physical Reconditioning Associated With Specific Nutritional Supplementation in Obese Patients Suffering From Metabolic Syndrome (OBEFITT)

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2014 by University Hospital, Rouen
Sponsor:
Information provided by (Responsible Party):
University Hospital, Rouen
ClinicalTrials.gov Identifier:
NCT01326416
First received: March 29, 2011
Last updated: June 18, 2014
Last verified: June 2014

March 29, 2011
June 18, 2014
March 2011
December 2014   (final data collection date for primary outcome measure)
Total body fat mass [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Change in total body fat mass estimated by Dual-energy X-Ray Absorptiometry (DEXA).
total body fat mass [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Change in total body fat mass estimated by DEXA.
Complete list of historical versions of study NCT01326416 on ClinicalTrials.gov Archive Site
Weight [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Change in weight, visceral fat mass, total lean mass, Bone Mineral Density, clinical and biological parameters of metabolic syndrome, insulin resistance, vascular inflammation parameters, heart rate variability, quadriceps strength, ventilatory parameters and quality of life score.
Weight [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Change in weight, visceral fat mass, total lean mass, BMD, clinical and biological parameters of metabolic syndrome, insulin resistance, vascular inflammation parameters, heart rate variability, quadriceps strength, ventilatory parameters and quality of life score.
Not Provided
Not Provided
 
Evaluation of the Impact of Physical Reconditioning Associated With Specific Nutritional Supplementation in Obese Patients Suffering From Metabolic Syndrome
Evaluation of the Impact of Physical Reconditioning Associated With Specific Nutritional Supplementation in Obese Patients Suffering From Metabolic Syndrome. OBEFITT Study.

Android obesity contributes, via insulin resistance and endothelial dysfunction, to the development of cardiovascular atherosclerosis. It leads to poor quality of life. It is often associated with metabolic syndrome which includes, whatever the definitions used (National Education Cholesterol Program, NECP / Adult Treatment Panel III, ATP III or International Diabetes Federation, IDF), an increased waist measurement, an arterial high blood pressure and disorders of the glucide and lipid metabolism. The treatment of the current "epidemic" of obesity and metabolic syndrome in France (12.4 % of obese and 14 % of subjects with metabolic syndrome) thus requires new therapeutic approaches.

A well-balanced diet and a daily physical activity are the indispensable requirements for the treatment of obesity and metabolic syndrome. It is possible to associate it to pharmacological agents, but the results are often partial and transient. Preliminary data suggest that leucine or arginine supplementation could facilitate the loss of fat mass. Moreover, the physical exercise has also demonstrated benefits.

Sessions of physical reconditioning (aerobic work + muscular intensification) associated with a program of specific nutritional supplementation by a mixture of Leucine and Arginine (in the daytime) could improve the treatment of obese subjects affected by metabolic syndrome.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Obesity
  • Metabolic Syndrome
  • Dietary Supplement: L-Leucine and L-arginine
    Specific nutritional supplementation for six months by 30g per day of a mixture of amino acids (21 g L-Leucine and 9 g of L-arginine), to be distributed during each of the 3 main meals.
  • Other: Physical Reconditioning by a trainer
    Physical reconditioning sessions begin with a warm-up for five minutes for the type of effort made, and then correspond to a sporting course composed of elements of strength training and / or aerobic exercises and will be completed by a return to simple stretching and general advice on managing their physical life. The duration of each session will be 45 minutes at the beginning of the protocol and then gradually increased over time to achieve 1:30 of total physical activity at the end of protocol.
  • Active Comparator: S: Nutritional Supplementation alone
    Specific nutritional supplementation for six months by 30g per day of a mixture of amino acids (21 g of L-Leucine and 9 g of L-arginine), to distribute during each of the 3 main meals.
    Intervention: Dietary Supplement: L-Leucine and L-arginine
  • Active Comparator: A: Physical Reconditioning alone
    Physical reconditioning sessions led by a trainer three times a week for 6 months.
    Intervention: Other: Physical Reconditioning by a trainer
  • Active Comparator: AS: Physical Reconditioning + Nutritional Supplementation
    Association for six months of a specific nutritional supplementation by 21 g of L-Leucine and 9 g of L-arginine per day (to distribute during each of the 3 main meals) and of physical reconditioning sessions three times a week.
    Intervention: Other: Physical Reconditioning by a trainer
  • No Intervention: C: Lifestyle counseling
    Usual advice given in consultation on the need for a balanced diet and regular physical activity
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
100
December 2014
December 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Suffering from obesity (Body Mass Index (BMI) > 30kg.m-2) with a maximal weight of 135 kg
  • Suffering from metabolic syndrome (International Federation of Diabetes(FID) definition)
  • Hospitalized or followed in consultation
  • Age 18 to 55 years old
  • Not having recently participated in other clinical studies during the last days before pre-inclusion consultation
  • Affiliated to a National Insurance scheme
  • Having National Social Security insurance

Exclusion Criteria:

  • Asthma, chronic respiratory failure, obstructive chronic bronchitis
  • Current or recent Pneumothorax, recent pleural draining or biopsy, current hemoptysis, untreated / in course of treatment active tuberculosis
  • Coronaropathy, myocardiopathy, myocarditis, unstable cardiac failure, ventricular rhythm disorders
  • Severe Anemia
  • Severe inferior members Arteritis
  • Incapacity to walk or cycle
  • Severe renal failure (Creatinine Clearance <or = 30 mL/min)
  • Severe Sepsis
  • Psychiatric Disorders (Diagnostic and Statistical Manual - Revision 4 (DSM IV) criteria) such as schizophrenia, other psychoses or major depressive non treated syndromes
  • Severe or non treated Eating Disorders implicated in obesity (compulsive access, bulimia)
  • Patients under guardianship or with curators
  • Women in age of procreation without means of effective contraception
  • Pregnant or breast-feeding women
  • Taking medicates such as: proteinate powder (Protifar ®, SP95 ®, Orlistat (Xenical ®, Ally ®), exenatide (Byetta ®), sitagliptin (Januvia ®, Xelevia ®), vildagliptin (Galvus ®), sitagliptin-metformin (Janumet ®), Vildagliptin-metformin (Eucreas ®), tadalafil (Cialis ®) sildenafil (Viagra ®)
  • Drug addiction to opiates in the last six months
  • Alcohol or drug abuse
  • Infection by Human Immunodeficiency Virus (HIV) , viral hepatitis B and viral hepatitis C
  • Active addiction to smoking in more than 8 cigarettes a day
  • Understanding badly spoken or written French
  • Performed, in 2 to 3 days preceding the Dual-energy X-Ray Absorptiometry (DEXA) exam, of a bone scintigraphy or a digestive tract radiological examination with the use of barium type of contrast agent.
Both
18 Years to 55 Years
No
Contact: Vanessa FOLOPE, M.D. 0033 232 88 81 22 vanessa.folope@chu-rouen.fr
Contact: Pierre DECHELOTTE, M.D., Ph.D. 0033 232 88 81 22 pierre.dechelotte@chu-rouen.fr
France
 
NCT01326416
2008/066/HP
Yes
University Hospital, Rouen
University Hospital, Rouen
Not Provided
Not Provided
University Hospital, Rouen
June 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP